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BACKGROUND: This study examines changes in the ideal cardiovascular health (CVH) status and whether these changes are 
associated with incident cardiovascular disease (CVD) and mortality in the elderly Asian population.
METHODS AND RESULTS: In the Korea National Health Insurance Service– Senior cohort aged ≥60 years, 208 673 participants 
without prior CVD, including 109 431 who showed changes in CVH status, were assessed. The association of the changes 
in cardiovascular risk factors with incident CVD was assessed from 2004 to 2014 in the elderly (aged 60– 74 years) and very 
elderly (≥75 years) groups. During the follow- up period (7.1 years for CVD and 7.2 years for mortality), 19 429 incident CVD 
events and 24 225 deaths occurred. In both the elderly and very elderly participants, higher CVH status resulted in a lower risk 
of CVD and mortality. In the very elderly participants, compared with consistently low CVH, consistently high CVH (subhazard 
ratio, 0.41; 95% CI, 0.23– 0.73) was associated with a lower risk of CVD. This trend was consistently observed in the elderly 
population. In the very elderly participants, total cholesterol level was not informative enough for the prediction of CVD events. 
In both the elderly and very elderly groups, body mass index and total cholesterol were not informative enough for the predic-
tion of all- cause mortality.
CONCLUSIONS: In both the elderly and very elderly Asian populations without CVD, a consistent relationship was observed 
between the improvement of a composite metric of CVH and the reduced risk of CVD. Body mass index and total cholesterol 
were not informative enough for the prediction of all- cause mortality in both the elderly and very elderly groups.
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The leading cause of death in the elderly is car-diovascular disease (CVD). Prevention of cardio-vascular events in elderly participants presents a 
therapeutic challenge that goes beyond the general 
underrepresentation of the elderly in clinical trials.1,2
As a complementary prevention strategy for CVD, 
primary prevention, which prevents the development of 
CVD, is increasingly being emphasized.3 The American 
Heart Association developed a simple tool consisting of 
7 metrics (nonsmoking, ideal body weight, physical ac-
tivity, diet, blood pressure, fasting blood glucose, and 
total cholesterol level) to promote ideal cardiovascular 
health (CVH). The substantial benefits of high CVH and 
ideal metrics for the prevention of incident CVD events 
and mortality have been reported.4– 6 Among a group 
of middle- aged participants without CVD, there was a 
significant reduction of the CVD risk with the increase 
of ideal metrics and CVH score.6 However, whether 
changes in CVH status are related to the development 
of incident CVD and mortality is unknown in the elderly 
population.
By using the serial examination data of the Korean 
National Health Insurance Service (NHIS)– Senior co-
hort,7 this study examined changes in the ideal CVH 
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status and whether the improvement of CVH status 
was beneficial for the prevention of incident CVD and 
mortality in the elderly Asian population.
METHODS
All data and materials have been made publicly avail-
able at the NHIS of Korea. The data can be accessed 
on the National Health Insurance Data Sharing 
Service homepage of the NHIS (http://nhiss.nhis.
or.kr). Applications to use the NHIS data will be re-
viewed by the inquiry committee of research support 
and, once approved, raw data will be provided to the 
authorized researcher for a fee at several permitted 
sites.
Data were collected from the NHIS– Senior database, 
which included data for 558 147 individuals selected by 
a 10% simple random sampling method from a total 
of 5.5 million subjects aged ≥60 years in the National 
Health Information Database.8,9 The NHIS– Senior da-
tabase covers the following parameters: sociodemo-
graphic and socioeconomic information, insurance 
status, health checkup examinations, and records of 
participants’ medical and dental histories. These pa-
rameters were stratified to cover 13 years (2002– 2014) 
and anonymized to protect the privacy of individuals 
within the cohort study. This study was approved by the 
institutional review board of the Yonsei University Health 
System (4- 2020- 0674). The need for informed consent 
was waived. The NHIS– Senior database used in this 
study was established by the NHIS in Korea.
Study Population
From the Korean NHIS– Senior database, 312 736 par-
ticipants who had a health checkup between 2005 and 
2012 were selected, and follow- up data were reviewed 
until December 2014. The exclusion criteria were as 
follows: (1) participants who had an ischemic stroke or 
transient ischemic attack before enrollment (n=41 993), 
(2) participants who had a myocardial infarction before 
enrollment (n=6359), (3) participants who had a hem-
orrhagic stroke before enrollment (n=1357), (4) partici-
pants with vascular disease (n=10 498), (5) participants 
who had a malignancy before enrollment (n=27 514), (6) 
participants with a body mass index (BMI) of <18.5 kg/
m2 (n=10 139); and (7) those with missing data (n=6203). 
Finally, we included 208  673 participants, of whom 
109 431 had at least 2 health checkups and were with-
out CVD between the first and second examination.
CVH Metrics and Status
To characterize the ideal CVH status, we applied 6 
American Heart Association guideline metrics (total 
cholesterol level, fasting blood glucose level, blood 
pressure, BMI, cigarette smoking, and exercise) and 
the cutoff definition for ideal, intermediate, or poor sta-
tus for each CVH metric (Table S1).3 Information on 
these 6 metrics was obtained through routine health 
checks and laboratory measurements. At each test 
cycle, an interview and physical examination were per-
formed for each patient, and information on medical 
history and drug use was collected.
We stratified the participants into 3 groups accord-
ing to the number of ideal metrics as follows: high (5+ 
ideal metrics), moderate (3 or 4 metrics), and low (≤2 
metrics).4,5 A continuous 12- point CVH score assign-
ing 0 points for poor metrics, 1 point for intermediate 
metrics, and 2 points for ideal metrics was also calcu-
lated.10 Change in CVH status was examined between 
the first and second health checkups of the partici-
pants with 6 metrics at both time points. All the partici-
pants were required to be free of a CVD event between 
the first and second examinations (Figure S1).
Covariates
The sociodemographic variables included age, sex, 
economic status, and living in metropolitan cities. 
The baseline economic status was determined on 
the basis of the relative economic levels categorized 
CLINICAL PERSPECTIVE
What Is New?
• In both the elderly (aged 60– 74 years) and very 
elderly (aged ≥75 years) populations, a consist-
ent relationship was observed between the 
improvement of a composite metric of cardio-
vascular health and reducing the risk of cardio-
vascular disease.
• However, among the individual health factors, 
body mass index and total cholesterol were 
not informative enough for the prediction of all- 
cause mortality in both the elderly and very el-
derly populations.
What Are the Clinical Implications?
• Our findings highlight that improving the status 
of cardiovascular health is beneficial for the el-
derly and very elderly as well.
Nonstandard Abbreviations and Acronyms
ARIC Atherosclerosis Risk in Communities
CVH cardiovascular health
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into 10 levels according to their health insurance 
premiums in the index year. We obtained informa-
tion on selected comorbid conditions from inpatient 
and outpatient hospital diagnoses. Baseline comor-
bidities were defined using the medical claims and 
prescription drug information before the index date. 
To ensure diagnostic accuracy, the participants were 
considered to have comorbidities when their con-
dition was a discharge diagnosis or had been con-
firmed at least twice in an outpatient setting, in line 
with previous studies that used data from the NHIS 
database (Table S2).11,12
Outcomes
The primary outcome was time to first CVD (combi-
nation of coronary heart disease and ischemic stroke 
or systemic embolism). Coronary heart disease was 
defined from any discharge diagnoses (International 
Classification of Diseases , Tenth Revision (ICD- 10) 
codes for acute myocardial infarction [I21x and I22x], 
chronic ischemic heart disease [I25.2, I25.5, I25.6, 
I25.8, and I25.9], or procedure codes for coronary 
revascularization [M6551, M6552, M6561, M6563, 
M6562, M6564, M6571, M6572, M6634, O1641, 
OA641, O1642, OA642, O1647, and OA647]). Ischemic 
stroke was defined from any discharge diagnoses 
(ICD- 10 codes I63 and I64) with concomitant brain 
imaging studies. The accuracy of the diagnosis of an 
ischemic stroke based on the NHIS claims data was 
previously validated.9,12– 16 The definitions of the clinical 
outcomes are presented in Table S2. The same pa-
tient could have >1 study outcome during the study 
duration, but only the first event of each outcome was 
considered in the study.
The secondary outcome was mortality. Information 
on death (date and causes of death) was confirmed 
from the National Population Registry of the Korea 
National Statistical Office with unique personal iden-
tification numbers, in which the central registration 
of death was conducted on the basis of death certif-
icates.9,12– 16 The NHIS and National Statistical Office 
are national agencies serving all Korean residents, 
so this approach provides a complete event check. 
Follow- ups for CVD and mortality were conducted 
until December 2014. We also analyzed cause- 
specific mortality based on causes of death con-
firmed by Korean National Statistical Office, because 
health metrics can be related to non– CVD- related 
mortality.
Sensitivity Analysis
The analysis was repeated with 4 groups of changes 
in CVH status, as used in the Framingham Offspring 
Study.17 The change in the number of ideal metrics 
between the first and second health checkups as 
the exposure was evaluated in the Cox analysis by 
using the unchanged category as reference. We also 
investigated the associations of time- varying CVH 
and changes in the individual CVH metrics with the 
outcomes.
Statistical Analysis
The 2 steps of the analysis conducted in this study are 
summarized in Figure S1.
In the Cox proportional hazard regression analysis, 
CVH status between the first and fifth tests were used 
as time- varying variables. Of the 3 versions of CVH 
status (category CVH status [low, medium, and high], 
ideal number of metrics [range, 0– 6], and 12- point 
CVH score), only 1 version of CVH status was used in 
each Cox proportional hazard regression according to 
the purpose of each analysis. At each date of an event 
(CVD or death), the model used the CVH exposure 
before the event. Coronary heart disease and isch-
emic stroke/systemic embolism were investigated as a 
composite CVD end point as well as separate results. 
In the analysis of the composite CVD end point, the 
2025 participants had both the occurrence of coronary 
heart disease and ischemic stroke/systemic embolism. 
In this case, on the date of the first event, follow- up 
was stopped, and the composite CVD end point was 
measured. The Fine and Gray method was used to 
consider death as a competing risk when assessing 
the composite CVD end point, coronary heart disease, 
and ischemic stroke or systemic embolism.18 The pro-
portional hazards assumption was tested on the basis 
of Schoenfeld residuals.19
The changes in CVH categories between the first 
and second health examination yielded 9 possible 
combinations of CVH statuses. In these analyses, fol-
low- up for CVD and mortality began from the second 
examination. Participants with at least 1 missing CVH 
metric in the second examination were removed from 
analysis. The subhazard ratio (sHR) of CVD and haz-
ard ratio of all- cause mortality for each combination of 
changes in CVH status were computed in the models 
using the consistently low CVH as the reference cate-
gory. All models were adjusted for sex, age, economic 
status, Hospital Frailty Score, and living in metropolitan 
cities. The proportional hazard assumption was evalu-
ated by visual inspection of the survival curves and the 
Kolmogorov test.
The individuals without a second health checkup 
or those with CVD between the first and second 
health checkup were excluded from the analysis of 
the changes in CVH status. To account for attrition be-
tween included and excluded subjects, we conducted 
an additional analysis using inverse probability of attri-
tion weights. The weights for each individual were cal-
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the inverse of the estimated probabilities of being with-
out CVD and receiving the next health checkup. The 
weights were stabilized by the baseline variables of 
sex, age, economic status, Hospital Frailty Score, living 
in metropolitan cities, and comorbidities.
Because multiple comparisons were made on the 
CVH variables, we used the Bonferroni correction, the 
most conservative approach for declaring significance. 
Differences were significant if P<0.0083. The statisti-
cal analyses were performed using SAS version 9.4 
(SAS Institute, Cary, NC) and R version 3.3.2 (The R 




The study population included 208 673 participants 
free of CVD who had data on all 6 CVH metrics at 
baseline. The mean (SD) age of the study population at 
baseline was 70.6 years (5.4 years), and 42.5% of the 
population were men. The comparison of the baseline 
characteristics between the elderly (aged 60– 74 years) 
and very elderly participants (≥75 years) are presented 
in Table 1. Compared with the elderly participants, very 
elderly participants had more comorbidities including 
hypertension, diabetes mellitus, dyslipidemia, and os-
teoporosis (Table 1).
Prevalence of CVH Status During the Total 
Follow- Up Period
The baseline characteristics of the study population 
and the characteristics at each examination are pre-
sented in Table S3. The proportion of high CVH status 
was 5.7% at the first checkup. Those who attended 
5 examinations (the maximum) were more likely to be 
healthy, with the proportion of participants with a high 
CVH status of 14.1%. Distribution of the number of 
ideal cardiovascular health metrics at each wave was 
same in the total study population, and elderly and very 
elderly population.
Time- Varying CVH and Risks of CVD and 
Mortality
The median follow- up period starting from baseline was 
7.1 years (interquartile range [IQR], 4.6– 7.9 years) for CVD 
and 7.2 years (IQR, 4.9– 8.0 years) for mortality. During 
the follow- up period, 19 429 incident CVD events (9932 
coronary heart disease events and 11  522 ischemic 
stroke or systemic embolism events) and 24 225 deaths 
occurred. The median times to CVD (2.6 years [IQR, 
1.3– 4.0 years] versus 2.8 years [IQR, 1.3– 4.3 years], 
P=0.009) and all- cause death (3.1 years [IQR, 1.7– 4.5 
years] versus 3.3 years [IQR, 1.9– 4.7 years], P=0.001) 
were significantly short in the very elderly than elderly. 
The time to CVD and all- cause mortality according to 
baseline cardiovascular health is presented in Table S4. 
After adjustment of clinical variables and competing 
risk of mortality, in the very elderly participants, com-
pared with low CVH, moderate CVH (sHR, 0.82; 95% 
CI, 0.77– 0.87), and high CVH (sHR, 0.53; 95% CI, 0.46– 
0.61) were associated with a lower risk of CVD (Table 2). 
Similarly, CVD risk was significantly reduced for each 
additional time- varying ideal metric (sHR, 0.86; 95% 
CI, 0.84– 0.89) and point in the 12- point CVH score 
(sHR, 0.87; 95% CI, 0.85– 0.88; Table 2). Similar results 
were observed for all- cause mortality (Table  2), coro-
nary heart disease, ischemic stroke/systemic embolism 
(Table S5), and cause- specific mortality (Table S6). This 
trend was consistently observed in the elderly popula-
tion (aged 60– 74  years). The incidence rates for CVD 
and all- cause mortality according to the CVH category, 
Table 1. Baseline Characteristics
Characteristics





Age, mean (SD), y 68.5 (3.1) 79.2 (3.8) <0.001
Men 74 288 (44.4) 14 383 (34.8) <0.001
Economic status, 
0– 10
7.0 (4.0– 9.0) 7.0 (3.0– 9.0) <0.001
Low, 0– 4 52 329 (31.3) 13 235 (32.0)
Middle, 5– 7 39 700 (23.7) 8404 (20.3)
High, 8– 10 75 288 (45.0) 19 717 (47.7)
Living area
Small city or rural 
area
100 798 (60.2) 26 198 (63.3) <0.001
Metropolitan city 66 519 (39.8) 15 158 (36.7)
Hypertension 69 373 (41.5) 21 622 (52.3) <0.001
Diabetes mellitus 22 790 (13.6) 5874 (14.2) 0.002
Dyslipidemia 52 086 (31.1) 11 714 (28.3) <0.001
Osteoporosis 46 229 (27.6) 14 646 (35.4) <0.001
CVH status no. of ideal metrics
Low, 0– 2 69 905 (41.8) 15 824 (38.3) <0.001
Moderate, 3– 4 87 769 (52.5) 23 279 (56.3)
High, 5– 6 9643 (5.8) 2253 (5.4)
No. of ideal 
metrics, median 
(IQR)*
3.0 (2.0– 4.0) 3.0 (2.0– 4.0) <0.001
12- Point CVH 
score, median 
(IQR)†
7.0 (6.0– 9.0) 8.0 (6.0– 9.0) <0.001
Values are reported as number (%) unless otherwise indicated. The relative 
economic levels categorized into 10 levels according to their health insurance 
premiums. CVH indicates cardiovascular health; and IQR, interquartile range.
*The CVH metrics included nonsmoking, body weight, physical activity, 
blood pressure, fasting blood glucose, and total cholesterol.
†The continuous 12- point CVH score (range, higher score indicating higher 
CVH) was calculated by assigning 0 (poor), 1 (intermediate), and 2 (ideal) 
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number of ideal metrics, and level of 12- point CVH score 
at baseline are presented in Table 3.
The time- varying Cox proportional risk model for 
the association of individual CVH metrics with the 
occurrence of CVD event and all- cause mortality is 
presented in Table S7. In the very elderly participants, 
BMI and total cholesterol level were not appropriate for 
the prediction of CVD events and all- cause mortality. In 
the elderly participants, all 6 metrics were appropriate 
for the prediction of CVD events.
Table 2. Time- Varying Cox Proportional Hazard Model for Incident Cardiovascular Disease and All- Cause Mortality
CVH Status, No. of Ideal Metrics
Per Additional 
Ideal Metric*
Per 1- Point Increase in 
the CVH Score*Low, 0– 2 Moderate, 3– 4 High, 5– 6
Cardiovascular disease Adjusted subhazard ratio (95% CI)†
Elderly 60~74 y, n/total n=13 761/167 317 1 [Reference] 0.73 (0.71– 0.75)‡ 0.44 
(0.41– 0.47)‡
0.82 (0.81– 0.83)‡ 0.85 (0.85– 0.86)‡
Very elderly ≥75 y, n/total n=5668/41 356 1 [Reference] 0.82 (0.77– 0.87)‡ 0.52 
(0.46– 0.60)‡
0.86 (0.84– 0.88)‡ 0.87 (0.85– 0.88)‡
All- cause mortality Adjusted hazard ratio (95% CI)§
Elderly 60~74 y, n/total n=14 438/99 532 1 [Reference] 0.86 (0.82– 0.90)‡ 0.55 
(0.51– 0.58)‡
0.93 (0.91– 0.94)‡ 0.90 (0.89– 0.90)‡
Very elderly ≥75 y, n/total n=9787/41 356 1 [Reference] 0.95 (0.90– 1.00) 0.71 
(0.66– 0.77)‡
0.95 (0.93– 0.97)‡ 0.93 (0.92– 0.94)‡
CVH, indicates cardiovascular health.
*A linear model was used for the analysis, per additional ideal metric and per 1- point increase in the 12- point CVH score.
†Cardiovascular disease was adjusted for sex, age, economic status, Hospital Frailty Score, and living in metropolitan cities, and competing risk of death.
‡P<0.0083 for differences reported.
§All- cause mortality was adjusted for sex, age, economic status, Hospital Frailty Score, and living in metropolitan cities.
Table 3. Incidence Rates for Cardiovascular Disease and All- Cause Mortality According to Measures of Baseline 
Cardiovascular Health
Incidence Rate per 1000 Person- Years (95% CI)
Cardiovascular Disease All- Cause Mortality
Elderly, 60~74 y, N/Total 
N=14 260/173 109
Very Elderly, ≥75 y,  
N/Total 
N=6234/45 379
Elderly, 60~74 y, N/Total 
N=15 641/173 109
Very Elderly, ≥75 y,  
N/Total 
N=11 507/45 379
CVH status, no. of ideal metrics
Low, 0– 2 15.5 (15.1– 15.9) 29.3 (28.2– 30.5) 13.8 (13.5– 14.2) 43.2 (41.8– 44.6)
Moderate, 3– 4 11.3 (11.0– 11.6) 25.0 (24.1– 25.9) 12.6 (12.3– 12.5) 43.9 (42.8– 45.1)
High, 5– 6 6.4 (5.8– 7.1) 18.8 (16.3– 21.6) 9.8 (9.0– 10.6) 40.7 (37.0– 44.6)
CVH status per no. of ideal metrics
0 22.2 (19.8– 24.8) 41.8 (33.2– 51.9) 18.8 (16.7– 21.2) 53.3 (43.9– 64.1)
1 16.8 (16.1– 17.6) 31.4 (29.1– 33.8) 13.8 (13.2– 14.5) 40.3 (37.8– 42.9)
2 14.6 (14.2– 15.1) 28.1 (26.8– 29.5) 13.6 (13.2– 14.0) 43.9 (42.3– 45.6)
3 12.2 (11.8– 12.6) 26.2 (25.1– 27.4) 13.2 (12.8– 13.5) 44.0 (42.5– 45.5)
4 9.9 (9.5– 10.3) 23 (21.6– 24.4) 11.7 (11.2– 12.1) 43.8 (41.9– 45.7)
5 6.5 (5.8– 7.2) 19.6 (16.9– 22.6) 9.7 (8.9– 10.5) 42.1 (38.2– 46.3)
6 5.4 (3.5– 7.9) 9.3 (4.0– 18.4) 11.1 (8.4– 13.5) 24.1 (14.9– 36.8)
CVH status per points on the CVH score
1 or 2 33.6 (27.3– 40.9) 49.5 (31.4– 74.4) 27.1 (21.7– 33.4) 78.9 (56.4– 107.4)
3 or 4 22.8 (21.5– 24.1) 39.1 (35.3– 43.1) 19.7 (18.5– 20.9) 52.1 (47.9– 56.6)
5 or 6 16.1 (15.6– 16.6) 31.2 (29.7– 32.8) 15.2 (14.8– 15.7) 46.2 (44.4– 48.0)
7 or 8 12.3 (12.0– 12.6) 25.4 (24.4– 26.5) 12.6 (12.3– 12.9) 42.7 (41.5– 44.0)
9 or 10 8.8 (8.4– 9.1) 21.4 (20.2– 22.7) 10.2 (9.8– 10.6) 40.5 (38.8– 42.3)
≥11 6.4 (5.5– 3.5) 17.3 (14.0– 21.2) 9.0 (8.0– 10.1) 37.3 (32.4– 42.7)
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Changes in CVH Status from the First and 
Second Health Examinations
Changes in CVH status were investigated and cal-
culated in 109 431 individuals. The median interval 
for participants with all 6 metrics at both time points 
was 2.0  years (IQR, 1.6– 2.8  years). The character-
istics of the individuals included in this analysis, as 
compared with those of the participants, were not 
examined in the second checkup (n=97  566) and 
with CVD in the interval (n=1676), and are shown in 
Table S8.
Figures 1A and 1B and Figure S2 show that 22.1% 
(n=3740) of the very elderly participants had improved 
CVH mostly from low to moderate status (15.6%) and 
from moderate to high status (5.6%), and only 0.8% 
improved from low to high status. In 15.8% (n=2674) of 
the very elderly participants with worse cardiovascular 
health over time, 11.8% went from moderate to low, 
3.4% from high to moderate, and 1.5% from high to 
low cardiovascular health. Stable moderate CVH was 
more prevalent in the elderly women than in the elderly 
men (Figures 2A and 2B) but was similarly prevalent 
regardless of high or low economic status (Figures 2C 
and 2D). The baseline characteristics of the partici-
pants according to the patterns of the changes in CVH 
status are shown in Table S9.
Changes in CVH (First to Second) and 
Subsequent Incidence of CVD and 
Mortality
The median follow- up of the outcomes starting from the 
second checkup was 5.1 years (IQR, 3.2– 6.0 years) for 
CVD and 5.2 (IQR, 3.5– 6.1 years) for mortality, which 
resulted in 7745 incident CVD events (elderly, 5980 
and very elderly, 1765) and 8930 deaths (elderly, 6099 
and very elderly, 2831). Heatmaps (Figures  1 and 2) 
and Kaplan– Meier curves (Figure S3A and S3B)s were 
used to depict the crude rates of CVD incidence and 
all- cause mortality according to the patterns of change 
in CVH status in the different age groups. The inci-
dence, absolute difference rates, and adjusted sHRs 
for CVD and HRs for all- cause mortality are reported 
in Table 4 and Figure 3. After weighting to account for 
Figure 1. Heatmap of the unadjusted incidence rates of cardiovascular disease (CVD) (A) and all- cause mortality (B) 
according to the patterns of change in cardiovascular health between the first and second examinations in the elderly (60– 
74 years) and very elderly (≥75 years) populations.
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Figure 2. Heatmap of the unadjusted incidence rates of cardiovascular disease (CVD) and all- cause mortality according to 
the patterns of change in cardiovascular health between the first and second examinations for comparison between women 
and men (A and B) and between high and low- to- moderate economic status (C and D).
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attrition, the incidence, absolute difference rates, and 
adjusted sHRs for CVD and hazard ratios for all- cause 
mortality are reported in Table S10.
For the very elderly population (aged ≥75 years), the 
multivariable analysis with adjustment of competing 
risk of death showed that compared with the 
individuals with consistently low CVH status (CVD 
incident rate per 1000 person- years, 30.1; 95% CI, 
27.4– 33.0), the low- to- moderate (sHR, 0.80; 95% CI, 
0.69– 0.93), consistently moderate (sHR, 0.80; 95% 
CI, 0.72– 0.91), moderate- to- high (sHR, 0.47; 95% CI, 
0.35– 0.62), high- to- low (sHR, 0.27; 95% CI, 0.09– 
0.80), high- to- moderate (sHR, 0.66; 95% CI, 0.49– 
0.90), and consistently high CVH status groups (sHR, 
0.42; 95% CI, 0.23– 0.74) showed lower CVD risks 
(Table  4). In the elderly groups, compared with the 
individuals with consistently low CVH status, a lower 
CVD risk was observed in all of the other groups with 
the improvement of CVH status. The results were 
similar for all- cause mortality.
Number of participants according to changes in the 
levels of individual CVH metrics between the first and 
second examinations are presented in Table S11. The 
associations of the changes in the individual CVH met-
rics with the subsequent occurrence of incident CVD 
events and all- cause mortality are presented in Table 5 
and Table S12. Compared with the low- low group, the 
high- high group of total cholesterol level was associ-
ated lower risk of CVD event in elderly but not in the 
very elderly population (P interaction=0.005). In both 
the elderly and very elderly groups, compared with the 
low- low group, the high- high group of BMI and total 
cholesterol were not informative enough for prediction 
of all- cause mortality.
Sensitivity Analysis
The results for 4 groups of changes in the CVH score 
showed that the high (score of ≥8)- to- low (score of <8), 
low- to- high, and consistently high CVH status groups 
had lower risks of CVD and mortality compared with 
the consistently low group (Table S13).
DISCUSSION
Principal Findings
In this study, time- varying moderate and high meas-
ures of CVH were associated with lower risks of CVD 
and mortality than low CVH status in both the elderly 
and very elderly populations. In both the elderly and 
Figure 3. Hazard ratios of cardiovascular disease (green dots) and all- cause mortality (red dots) according to the pattern 
of change in the cardiovascular health status between the first and second health examinations in the elderly (60– 74 years) 
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very elderly populations, consistent relationships were 
found between the improvement of the composite 
metric of CVH and the reduced risk of CVD. However, 
among the individual health factors, total cholesterol 
level was not appropriate for the prediction of CVD 
events in the very elderly participants. BMI and total 
cholesterol level were not appropriate for the predic-
tion of all- cause mortality in both the elderly and very 
elderly groups. This study is showing that improving 
CVH status is beneficial for both the elderly and very 
elderly populations.
CVH Metrics in the Very Elderly 
Population
The recently published European Society of Cardiology 
and European Atherosclerosis Society guidelines ex-
tended the age of the risk assessment system from 
65 years to 70 years and recommended statin use for 
primary prevention according to the individual level of 
risk until aged 75 years.20 With this in mind, we have 
defined very elderly as referring to individuals aged 
>75 years herein.
The present study found that in the overall Asian 
very elderly population, 61.8%, 21.8%, and 16.3% of 
the participants showed stable, improved, and deteri-
orated CVH, respectively. This trend is consistently ob-
served in both the very elderly and elderly populations. 
This study had a higher number of participants with im-
proved health metrics than other studies.6,21,22 This can 
be related with the high proportion of participants with 
intermediate or ideal BMI and physical activity in the 
Asian elderly cohort. Worldwide, 31.1% (95% CI, 30.9– 
31.2) of adults are physically inactive, with proportions 
ranging from 17.0% (95% CI, 16.8– 17.2) in Southeast 
Asia to about 43% in the Americas and Eastern 
Mediterranean regions. Adults aged 60 years or older 
from Southeast Asia are much more active than are 
individuals of the same age from all other regions, and 
more active than are young adults (aged 15– 29 years) 
from the Americas, the Eastern Mediterranean, Europe, 
and the western Pacific regions.23
The National Health and Nutrition Examination 
Surveys21 of the United States found that the preva-
lence of smoking, hypercholesterolemia, and hyper-
tension decreased significantly, but the prevalence of 
obesity and diabetes mellitus increased significantly. 
However, dietary and physical activity levels were un-
changed from 1988/1994 to 2008. In the elderly Asian 
cohort of this study, the proportion of participants 
with ideal body weights was >60%. Moreover, those 
of the participants with intermediate or ideal physical 
activity levels were 28.5% and 64.2% in the first and 
second health examinations, respectively. This can be 
explained by the fact that this study included only in-
dividuals aged >60 years. In the ARIC (Atherosclerosis 
Risk in Communities) study,22 the general trend was 
a decrease in the number of ideal metrics, with only 
7% of the participants showing improved CVH over 
26  years from 1987 to 2013. In a UK general com-
munity (Whitehall II), 13% of the participants showed 
improved CVH. The baseline mean ages of the partic-
ipants in the ARIC and Whitehall II studies were 52.1 
and 44.8 years, respectively.6 Moreover, the ideal other 
individual CVH metrics, including smoking habit, were 
high in this study.
CVH Change and CVD Disease
The relationship between change of CVH and CVD 
event is still controversial. In the ARIC study,22 the im-
provement in CVH through follow- up over 26  years 
was associated with a lower prevalence of CVD (no 
data on incident CVD) and better cardiac structure and 
function. In addition, in the Framingham Heart Study,10 
loss of ideal CVH metrics over 6  years was not sta-
tistically significantly associated with coronary artery 
calcification progression after adjustment for the num-
ber of baseline ideal metrics. In the Whitehall II study,6 
time- varying moderate and high measures of CVH 
were associated with a lower CVD risk than low CVH. 
However, no consistent relationship was observed 
between the direction of change in the category of a 
composite metric of CVH and the risk of CVD.
In this study, the time- varying moderate and high 
measures of CVH were associated with lower CVD and 
mortality risks than low CVH status in both the elderly 
and very elderly populations. In the elderly group, com-
pared with the persistently low CVH group, the CVD 
risk was decreased in all of the other groups. By con-
trast, compared with the very elderly individuals with 
persistently low CVH status (consistently low group), 
all of the other groups except the low- to- moderate 
and low- to- high groups had a decreased CVD risk. 
Because the very elderly population with low baseline 
CVH status did not show decreased CVD risk even 
after improvement of their health metrics, the effect of 
baseline health condition might be more important in 
the very elderly population.
Individual CVH Metrics and CVD Risk in 
the Very Elderly Population
Because of the lack of data in the very elderly partici-
pants, there are no clinical support tools specifically de-
signed to assess cardiovascular risk in this population. 
Statin therapy, blood pressure control, smoking cessa-
tion, physical activity, and maintaining a normal body 
weight are interventions that have been shown to re-
duce the incidence of primary cardiovascular events in 
the very elderly. The present study showed that main-
taining optimal BMI and cholesterol level were not re-
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elderly population. No significant association of BMI 
with outcomes might be attributable to the obesity par-
adox.24,25 For example, obesity is associated with mor-
tality at a younger age, but not at an older age. Thus, 
the association might be driven by this age difference.
The association between weight loss and car-
diovascular mortality is less clear in the very elderly 
population. Ghaem Maralani et al reported that obe-
sity increased risk of CVD- related death only in those 
aged <70 years, but not in those aged ≥70 years.26 
Takata et al observed a similar outcome that cardio-
vascular mortality was 78% less in overweight oc-
togenarians than in those who were underweight.27 
Thus, although dietary recommendations can be 
made for the very elderly participants, weight loss 
recommendations for this population are not well 
supported by the literature.
The best available evidence for the primary prevention 
of cardiovascular events in older adults supports the use 
of statin therapy and blood pressure control. This study 
showed ideal total cholesterol was positively associated 
with CVD events in elderly participants. It can be a bene-
fit from lipid- lowering therapy. Statin therapy reduces the 
risk of myocardial infarction and stroke, although close 
monitoring for adverse events is warranted. It was the 
same in the Asian very elderly (≥75 years) population.28 
However, in participants aged >75 years because of the 
lack of evidence, the American College of Cardiology/
American Heart Association guidelines on the treat-
ment of blood cholesterol to reduce cardiovascular risk 
in adults do not recommend using their atheroscle-
rotic risk calculator. It is suggested that therapy could 
be considered on the basis of a discussion of benefits 
and risks, adverse effects, drug interactions, and patient 
preference.29
LIMITATIONS
This study has several limitations. First, studies that 
use administrative databases might be susceptible to 
errors arising from coding inaccuracies. To minimize 
this problem, we applied the definition that has been 
previously validated in previous studies that used the 
Korean NHIS sample cohort.9,12– 16 Second, the individ-
uals excluded from the analysis of the changes in CVH 
had a less favorable cardiovascular risk profile, which 
could lead to an underestimation of the reported as-
sociations. To check this problem, we did an analysis 
with weighting to account for attrition. The weighted 
result to account for attrition was consistent with the 
main result. Third, the changes in the distribution of 
CVH across repeated examinations might have partly 
been related to aging, temporal trends, and cohort at-
trition. Fourth, some categories of CVH change were 
small, which might explain why some associations are 
not statistically significant.
CONCLUSIONS
In both the elderly and very elderly populations, a 
consistent relationship was observed between the 
improvement of a composite metric of CVH and re-
ducing the risk of CVD. However, among the indi-
vidual health factors, total cholesterol level was not 
appropriate for the prediction of CVD events in the 
very elderly participants. BMI and total cholesterol 
level were not appropriate for the prediction of all- 
cause mortality in both the elderly and very elderly 
groups.
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Table S1. Definition of cardiovascular health metrics according to the American Heart 
Association for ascertainment of cardiovascular health status. 
Metric 
Optimal Intermediate Poor 
2 point 1 point 0 point 
Smoking Never or quit ≥12 months Quit <12 months Current smokers 
Body mass 
index 
<25 kg/m2 25-29.9 kg/m2 ≥30 kg/m2 
Physical 
activity a 
≥75 min/week of vigorous 
activity, ≥150 min/week of 
moderate activity or a 
combination of the two 
1–74 min/week vigorous 
activity, 1–149 min/week 
moderate activity or a 




<120/80 mmHg, untreated 
<120/80 mmHg on treatment 




<100 mg/dL, untreated 
100-126 mg/dL 






or <200mg/dL treated 
>240 mg/dL 
a. Physical activity was assessed using questions on frequency and duration of participation in mildly 
energetic (e.g., weeding, general housework, bicycle repair), moderately energetic (e.g., dancing, 
cycling, leisurely swimming), and vigorous physical activity (e.g., running, hard swimming, playing 
squash). 
b. Systolic blood pressure was measured twice with a sphygmomanometer in the sitting position after 
5 min rest, and the average of the two readings was used in the present analyses.  
c. Fasting blood glucose and total cholesterol were measured using standardized methods.  
SI conversion factor: To convert cholesterol to millimoles per liter, multiply by 0.0259. 






 http://ahajournals.org by on July 22, 2021
Table S2. Definitions and ICD-10 codes used for defining the comorbidities and clinical 
outcomes. 
 Definitions ICD-10 codes or conditions 
Comorbidities   
Atrial fibrillation 12,14,30 Defined from diagnosis* ICD-10: I48 
Heart failure 14,30 Defined from diagnosis* ICD-10: I11.0, I50, I97.1 
Hypertension 14,15, 30 Defined from diagnosis* 
ICD-10: I10, I11, I12, I13, I15 and 
antihypertensive medication 
Diabetes mellitus 14, 30 
Defined from diagnosis* plus 
treatment 
ICD-10: E10, E11, E12, E13, E14 
Treatment: all kinds of oral 
antidiabetics and insulin. 
Dyslipidemia 14, 30 Defined from diagnosis* ICD-10: E78 
Ischemic stroke 14, 30 Defined from diagnosis* ICD-10: I63, I64 
Transient ischemic 
attack 14, 30 
Defined from diagnosis* ICD-10: G45 
Hemorrhagic stroke Defined from diagnosis* ICD-10: I60, I61, I62 
Myocardial infarction 31 Defined from diagnosis* ICD-10: I21, I22, I25.2 
Coronary heart disease 
Defined from a history of 
acute myocardial infarction, 
coronary revascularization, 
or chronic ischemic heart 
disease. 
Acute myocardial infarction: 
admission diagnosis (ICD-10: 
I21, I22) concurrently with 
coronary angiography (HA670, 
HA680, HA681) 
Coronary revascularization: 
percutaneous coronary intervention 
(M6551, M6552, M6561, M6563, 
M6562, M6564, M6571, M6572), 
thrombolytic treatment (M6634), or 
coronary artery bypass graft 
(O1641, OA641, O1642, OA642, 
O1647, OA647) 
Chronic ischemic heart disease: 
diagnosis* (ICD-10: I25.2, I25.5, 
I25.6, I25.8, I25.9) 
Peripheral arterial 
disease 14, 30 
Defined from diagnosis* 
ICD-10: I70.0, I70.1, I70.2, I70.8, 
I70.9 
Chronic kidney disease 
14, 30 
Defined from eGFR or 
diagnosis* 
(if laboratory value was not 
available, diagnosis code was 
used) 
eGFR <60mL/min per 1.73 m2  
ICD-10: N18, N19 
End-stage renal disease 
32 
Defined from national 
registry for severe illness. 
Patients with end-stage renal disease 
undergoing chronic dialysis or 
received a kidney transplant. 
Hypertrophic 
cardiomyopathy 33 
Defined from at least one 
records of either inpatient or 
outpatient diagnoses 
ICD-10: I42.1, I42.2 
Sleep apnea Defined from diagnosis* ICD-10: G47.3 
Proteinuria 
Defined from laboratory data 
(if laboratory value was not 
available, diagnosis code was 
used) 
Urine dipstick proteinuria 1+ or 
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Osteoporosis 34 Defined from diagnosis* 
ICD-10: M80, M81, M82 (except 
M82.0) 
Hyperthyroidism Defined from diagnosis* ICD-10: E05 
Hypothyroidism Defined from diagnosis* ICD-10: E03 
Chronic Liver disease 
Defined from diagnosis of 
chronic liver disease, 
cirrhosis, and hepatitis 
ICD-10: B18, K70, K71, K72, K73, 
K74, K76.1 
Chronic obstructive 
pulmonary disease 35 
Defined from diagnosis* plus 
treatment 
ICD-10: J42, J43(except J43.0), J44 
Treatment: SABA, SAMA, LABA, 
LAMA, ICS, ICS+LABA, or 
methylxanthine (>1 months). 
Malignancy 
Defined from diagnoses of 
cancer (non-benign) 
ICD-10: C00-C97 
Clinical outcomes   
Coronary heart disease 
Defined from an event of 
acute myocardial infarction, 
coronary revascularization, 
or death of which the 
cause was recorded as a 
coronary artery disease or 
myocardial infarction 
Acute myocardial infarction: 
admission diagnosis (ICD-10: 
I21, I22) concurrently with 
coronary angiography (HA670, 
HA680, HA681) 
Coronary revascularization: 
percutaneous coronary intervention 
(M6551, M6552, M6561, M6563, 
M6562, M6564, M6571, M6572), 
thrombolytic treatment (M6634), or 
coronary artery bypass graft 
(O1641, OA641, O1642, OA642, 
O1647, OA647) 
Coronary artery disease or 
myocardial infarction:  
ICD-10: I20, I21, I22, I23, I25 
Ischemic stroke 12, 30 
Defined from any discharge 
diagnoses with concomitant 
imaging studies 
ICD-10: I63, I64 
Systemic embolism 
Defined from admission 
diagnosis or related death 
ICD-10: I74, N280 (including renal 
infarction) 
Abbreviations: eGFR, estimated glomerular filtration rate; ICD-10, International Classification of 
Diseases-10th Revision. 
*To ensure accuracy, comorbidities were established based on one inpatient or two outpatient records 
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Age, mean (SD), year 70.6 (5.4) 72.5 (4.4) 73.1 (4.5) 74.4 (4.2) 75.6 (3.9) 
Men 88671 (42.5) 44867 (41.0) 52484 (43.8) 44604 (48.1) 18263 (53.3) 
Economic status, 0-10 7 (4, 9) 7 (4, 9) 8 (4, 9) 8 (4, 9) 8 (4, 9) 
  Low, 0-4 65564 (31.4) 33793 (29.9) 31813 (27.4) 23504 (26.1) 8679 (26.0) 
  Middle, 5-7 48104 (23.1) 24715 (21.9) 25416 (21.9) 19170 (21.3) 6745 (20.2) 
  High, 8-10 95005 (45.5) 54372 (48.2) 58715 (50.6) 47348 (52.6) 17911 (53.7) 
Living area      
Small city or rural area 126996 (60.9) 65923 (58.4) 71273 (61.5) 58135 (64.6) 21319 (64.0) 
  Metropolitan city 81677 (39.1) 46957 (41.6) 44671 (38.5) 31887 (35.4) 12016 (36.0) 
Hypertension 90995 (43.6) 59834 (58.1) 66663 (59.8) 56099 (64.5) 22009 (68.2) 
Diabetes mellitus 28664 (13.7) 18134 (16.1) 20601 (17.8) 17694 (19.7) 7060 (21.2) 
Dyslipidemia 63800 (30.6) 46957 (41.6) 57936 (50.0) 51774 (57.5) 20538 (61.6) 
Osteoporosis 60875 (29.2) 42228 (37.4) 49993 (43.1) 43267 (48.1) 16697 (50.1) 
CVH status, No. of ideal metrics a     
Low, 0-2 85729 (41.1) 44096 (40.3) 32602 (28.4) 23604 (26.3) 8509 (25.6) 
Moderate, 3-4 111048 (53.2) 59028 (53.9) 67736 (58.9) 54012 (60.1) 20090 (60.4) 
High, 5-6 11896 (5.7) 6307 (5.8) 14641 (12.7) 12283 (13.7) 4685 (14.1) 
No. of ideal metrics, 
Median (IQR) a 
3 (2, 4) 3 (2,4) 3 (2,4) 3 (2,4) 3 (2,4) 
12-Point CVH score, 
Median (IQR) b 
7 (6, 9) 8 (6,9) 9 (7,10) 9 (8,10) 9 (8,10) 
Abbreviations: CVH, cardiovascular health; IQR, interquartile range, SD, standard deviation. 
Values are reported as No. (%) unless otherwise indicated.  
a. The cardiovascular health metrics included nonsmoking, body weight, physical activity, blood 
pressure, fasting blood glucose, and total cholesterol. 
b. The continuous 12-point CVH score (range, higher score indicating higher CVH) was calculated by 
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Table S4. The time to cardiovascular disease and all-cause mortality according to measures of baseline cardiovascular health. 
 The Time (years) to Cardiovascular Disease The Time (years) to All-Cause Mortality 
 60~74 years 
(No./Total No.= 
14,260/173,109) 











CVH status, No. of ideal metrics 
Low, 0-2 2.7 [1.2; 4.2] 2.6 [1.4; 4.0] 0.627 3.2 [1.8; 4.6] 3.2 [1.8; 4.7] 0.792 
Moderate, 3-4 2.9 [1.4; 4.3] 2.5 [1.2; 4.1] 0.001 3.3 [2.0; 4.7] 3.1 [1.7; 4.4] 0.001 
High, 5-6 2.6 [1.3; 4.2] 2.6 [1.5; 4.2] 0.963 3.4 [1.8; 4.8] 2.8 [1.6; 4.3] 0.139 
CVH status per No. of ideal metrics 
0 2.5 [1.1; 3.9] 2.6 [1.4; 4.4] 0.614 3.6 [2.1; 4.7] 3.4 [1.3; 4.9] 0.611 
1 2.6 [1.2; 4.1] 2.8 [1.3; 4.0] 0.714 3.3 [1.8; 4.6] 3.5 [1.8; 4.7] 0.423 
2 2.7 [1.3; 4.2] 2.6 [1.4; 4.0] 0.623 3.2 [1.8; 4.6] 3.1 [1.8; 4.6] 0.566 
3 2.8 [1.4; 4.3] 2.4 [1.2; 4.1] 0.003 3.3 [2.0; 4.7] 3.1 [1.7; 4.4] 0.001 
4 2.9 [1.4; 4.4] 2.8 [1.3; 4.0] 0.108 3.4 [1.9; 4.7] 3.2 [1.8; 4.4] 0.018 
5 & 6 2.6 [1.3; 4.2] 2.6 [1.5; 4.2] 0.963 3.4 [1.8; 4.8] 2.8 [1.6; 4.3] 0.139 
CVH status per points on the CVH score      
≤4 2.6 [1.3; 4.1] 2.7 [1.4; 4.0] 0.724 3.4 [1.9; 4.7] 3.6 [1.7; 4.7] 0.927 
5 or 6 2.8 [1.3; 4.2] 2.6 [1.2; 3.9] 0.070 3.3 [1.9; 4.7] 3.2 [1.8; 4.6] 0.365 
7 or 8 2.8 [1.4; 4.3] 2.6 [1.3; 4.1] 0.081 3.3 [1.9; 4.7] 3.1 [1.8; 4.5] 0.037 
9 or 10 2.8 [1.3; 4.4] 2.5 [1.3; 4.1] 0.375 3.3 [1.9; 4.6] 3.0 [1.6; 4.3] 0.003 
11  2.3 [1.0; 3.9] 2.1 [1.4; 3.3] 0.865 3.1 [1.6; 4.8] 2.5 [1.6; 3.9] 0.357 
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Table S5. Time-varying Cox proportional hazard model for incident coronary heart disease and ischemic stroke / systemic embolism as separate 
outcomes. 
 
Adjusted Subhazard Ratio a (95% CI) 
CVH Status, No. of Ideal Metrics Per Additional 
Ideal Metric 
Per 1-Point 
Increase in the 
CVH Score Low, 0-2 Moderate, 3-4 High, 5-6 
Coronary heart disease       
Elderly (60~74 years) 
(No./total No.= 6,764/167,317) 
1 (Ref) 0.66 (0.56-0.76) 0.80 (0.75-0.86) 0.79 (0.78-0.81) 0.83 (0.81-0.84) 
Very-elderly ( 75 years) 
(No./total No.=3,168/41,356) 
1 (Ref) 0.81 (0.56-1.18) 0.83 (0.69-0.99) 0.87 (0.84-0.91) 0.88 (0.85-0.90) 
Ischemic stroke / systemic embolism       
Elderly (60~74 years) 
(No./total No.=8,192/167,317) 
1 (Ref) 0.86 (0.73-1.01) 0.90 (0.83-0.97) 0.84 (0.82-0.86) 0.85 (0.84-0.86) 
Very-elderly ( 75 years) 
(No./total No.= 3,330/41,356) 
1 (Ref) 0.70 (0.80-0.97) 0.78 (0.67-0.91) 0.88 (0.84-0.91) 0.87 (0.85-0.89) 
Abbreviations: CI, confidence interval; CVH, cardiovascular health. 
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Table S6. Time-varying Cox proportional hazard model for cause-specific mortality. 
Cause of death 
Elderly (60~74 years) 
(n=167,317) 
Very-elderly ( 75 years) 
(n=41,356) 
No. event Adjusted HR (95% CI) No. event Adjusted HR (95% CI) 
Cardiovascular death 2774  2421  
Cardiovascular health status     
Low (0-2 ideal metrics)  1 (Ref)  1 (Ref) 
Moderate (3-4 ideal metrics)  0.79 (0.73-0.86)  0.86 (0.79-0.93) 
High (5-6 ideal metrics)  0.56 (0.48-0.66)  0.63 (0.52-0.76) 
Per additional ideal metric  0.86 (0.83-0.89)  0.90 (0.87-0.93) 
Per end-point increase in CVH score  0.84 (0.83-0.86)  0.89 (0.87-0.91) 
Cancer 6230  2588  
Cardiovascular health status     
Low (0-2 ideal metrics)  1 (Ref)  1 (Ref) 
Moderate (3-4 ideal metrics)  0.97 (0.92-1.03)  1.01 (0.93-1.10) 
High (5-6 ideal metrics)  0.84 (0.76-0.93)  1.01 (0.86-1.18) 
Per additional ideal metric  0.97 (0.95-0.99)  1.0 (0.97-1.04) 
Per end-point increase in CVH score  0.94 (0.93-0.95)  0.97 (0.95-0.99) 
Other causes 5434  4778  
Cardiovascular health status     
Low (0-2 ideal metrics)  1 (Ref)  1 (Ref) 
Moderate (3-4 ideal metrics)  0.87 (0.82-0.92)  0.95 (0.90-1.01) 
High (5-6 ideal metrics)  0.73 (0.66-0.81)  0.73 (0.64-0.83) 
Per additional ideal metric  0.93 (0.91-0.95)  0.95 (0.93-0.98) 
Per end-point increase in CVH score  0.88 (0.87-0.90)  0.94 (0.92-0.95) 
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Table S7. Time-varying Cox proportional hazard models for the association between individual cardiovascular health metrics and incident 
cardiovascular disease and all-cause mortality. 
Level of cardiovascular 
health metric 
Adjusted Subhazard Ratio (95% CI) a Adjusted Hazard Ratio (95% CI) b 
Incident cardiovascular disease  All-cause mortality 
Elderly (60~74 years) 
(No./Total No.= 
14,260/173,109) 
Very-elderly ( 75 years) 
 (No./Total No.= 
6,234/45,379) 
Elderly (60~74 years) 
 (No./Total No.= 
15,641/173,109) 
Very-elderly ( 75 years) 
 (No./Total No.= 
11,507/45,379) 
Smoking     
  Poor 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
  Intermediate 0.79 (0.71-0.87) 0.79 (0.64-0.98) 0.71 (0.67-0.75) 0.71 (0.67-0.75) 
  Ideal 0.76 (0.71-0.81) 0.73 (0.64-0.83) 0.69 (0.67-0.71) 0.69 (0.67-0.71) 
Body mass index       
 Poor 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
  Intermediate 0.91 (0.78-1.04) 0.80 (0.59-1.08) 0.89 (0.80-0.99) 1.0 (0.86-1.18) 
 Ideal 0.81 (0.70-0.94) 0.87 (0.65-1.16) 1.08 (0.97-1.19) 1.29 (1.10-1.50) 
Physical activity       
  Poor 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
  Intermediate 0.82 (0.77-0.87) 0.82 (0.72-0.93) 0.75 (0.72-0.78) 0.92 (0.87-0.97) 
  Ideal 0.73 (0.68-0.78) 0.80 (0.70-0.92) 0.75 (0.71-0.78) 0.80 (0.75-0.85) 
Blood pressure       
  Poor 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
  Intermediate 0.82 (0.77-0.86) 0.87 (0.79-0.96) 0.93 (0.90-0.97) 0.96 (0.92-1.0) 
 Ideal 0.59 (0.54-0.65) 0.65 (0.53-0.78) 0.87 (0.82-0.91) 0.98 (0.91-1.05) 
Total cholesterol       
 Poor 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
 Intermediate 0.79 (0.73-0.85) 0.90 (0.78-1.04) 0.93 (0.88-0.98) 0.97 (0.90-1.03) 
 Ideal 0.72 (0.67-0.77) 0.87 (0.75-1.01) 1.06 (1.01-1.12) 1.13 (1.06-1.21) 
Fasting glucose       
 Poor 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
  Intermediate 0.71 (0.66-0.77) 0.73 (0.66-0.84) 0.69 (0.65-0.72) 0.76 (0.71-0.80) 
 Ideal 0.59 (0.55-0.64) 0.67 (0.58-0.77) 0.61 (0.58-0.64) 0.69 (0.65-0.73) 
Abbreviations: CI, confidence interval.  
a. Each individual cardiovascular health metric was included as a time-varying variable. Subhazard ratios were adjusted for sex, age, economic status, 
Hospital Frailty Score, living in metropolitan cities, and competing risk of death. 
b. Each individual cardiovascular health metric was included as a time-varying variable. Hazard ratios were adjusted for sex, age, economic status, 
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P-value b All 
(N=99242) 
Exclusion due to no 
second examination 
(N=97566) 
Exclusion due to CVD 
event within interval 
(N=1676) 
Baseline characteristics      
Age, mean (SD), y 70.4 (4.4) 70.8 (6.3) 70.8 (6.3) 71.3 (4.6) <0.001 
Men 49296 (45.0) 39375 (39.7) 38431 (39.4) 944 (56.3) <0.001 
Economic status, 0-10 7 (4, 9) 7 (4, 9) 7 (4, 9) 7 (4, 9) 0.015 
Hypertension 46978 (42.9) 44017 (44.4) 43103 (44.2) 914 (54.5) <0.001 
Diabetes mellitus 14207 (13.0) 14457 (14.6) 14115 (14.5) 342 (20.4) <0.001 
Dyslipidemia 33779 (30.9) 30021 (30.3) 29363 (30.1) 658 (39.3) <0.001 
Chronic kidney disease 1076 (1.0) 1144 (1.2) 1122 (1.1) 22 (1.3) 0.615 
Anemia 16376 (15.0) 17420 (17.6) 17179 (17.6) 241 (14.4) 0.001 
History of bleeding 2190 (2.0) 2177 (2.2) 2142 (2.2) 35 (2.1) 0.831 
Hyperthyroidism 2614 (2.4) 2510 (2.5) 2470 (2.5) 40 (2.4) 0.767 
Hypothyroidism 2701 (2.5) 2510 (2.5) 2469 (2.5) 41 (2.4) 0.889 
COPD 7048 (6.4) 7176 (7.2) 7020 (7.2) 156 (9.3) 0.001 
Liver disease 22698 (20.7) 19677 (19.8) 19271 (19.8) 406 (24.2) <0.001 
Hypertrophic cardiomyopathy 187 (0.2) 174 (0.2) 167 (0.2) 7 (0.4) 0.036 
Osteoporosis 32097 (29.3) 28778 (29.0) 28305 (29.0) 473 (28.2) 0.497 
Baseline cardiovascular health      
CVH status, No. of ideal metrics c     <0.001 
Low, 0-2 44096 (40.3) 41633 (42.0) 40828 (41.8) 805 (48.0)  
Moderate, 3-4 59028 (53.9) 52020 (52.4) 51194 (52.5) 826 (49.3)  
High, 5-6 6307 (5.8) 5589 (5.6) 5544 (5.7) 45 (2.7)  
No. of ideal metrics, median (IQR) c 3 (2, 4) 3 (2, 4) 3 (2, 4) 3 (2, 3) <0.001 
12-Point CVH score, median (IQR) d 8 (6, 9) 7 (6, 9) 7 (6, 9) 7 (6, 8) <0.001 
Abbreviations: COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; CVH, cardiovascular health; IQR, interquartile range, SD, 
standard deviation. 
a. Excluded participants are comprised of those who died in the interval (n=248), those who had a CVD event in the interval (n=468), those who dropped 
out (n=924) and those with incomplete CVH metrics (n=1290). 
b. P-value for contrast between included and excluded participants, derived from Pearson, chi-square and t-test where appropriate. 
c. The cardiovascular health metrics included nonsmoking, body weight, physical activity, blood pressure, fasting blood glucose, and total cholesterol. 
d. The continuous 12-point CVH score (range, higher score indicating higher CVH) was calculated by assigning 0 (poor), 1 (intermediate), and 2 (ideal) 
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Table S9. Baseline characteristics by pattern of change in cardiovascular health. 
 Pattern of change 
Low-Low Low-Mod Low-High Mod-Low Mod-Mod Mod-High High-Low High-Mod High-High 
(N=25909) (N=17331) (N=856) (N=13560) (N=39760) (N=5708) (N=440) (N=3872) (N=1995) 
Age, mean (SD) 70.2 (4.3)    70.5 (4.4)   70.5 (4.4)    70.3 (4.4)    70.6 (4.5)   70.6 (4.4)   70.8 (4.7)   70.4 (4.4)   70.2 (4.1)  
Men 12096 (46.7) 7940 (45.8) 416 (48.6) 6538 (48.2) 17211 (43.3) 2398 (42.0) 232 (52.7) 1658 (42.8) 807 (40.5) 
Economic Status, 0-10  7 (3, 9)  7 (4, 9)  7 (4, 9)  7 (3, 9)  7 (4, 9)  7 (4, 9)  7 (4, 9)  7 (4, 9)  8 (4, 9) 
Hypertension 15808 (61.0) 8246 (47.6) 159 (18.6) 5943 (43.8) 14934 (37.6) 1040 (18.2) 68 (15.5) 584 (15.1) 196 (9.8) 
Diabetes mellitus 7171 (27.7) 2390 (13.8) 19 (2.2) 1522 (11.2) 2963 (7.5) 67 (1.2) 5 (1.1) 53 (1.4) 17 (0.9) 
Dyslipidemia 11826 (45.6) 5592 (32.3) 150 (17.5) 4108 (30.3) 10112 (25.4) 974 (17.1) 65 (14.8) 610 (15.8) 342 (17.1) 
Chronic kidney disease 348 (1.3) 154 (0.9) 7 (0.8) 139 (1.0) 348 (0.9) 47 (0.8) 3 (0.7) 21 (0.5) 9 (0.5) 
Anemia 2891 (11.2) 2286 (13.2) 130 (15.3) 1873 (13.8) 6783 (17.1) 1077 (18.9) 84 (19.1) 807 (20.8) 445 (22.3) 
History of bleeding 548 (2.1) 322 (1.9) 11 (1.3) 257 (1.9) 802 (2.0) 121 (2.1) 7 (1.6) 84 (2.2) 38 (1.9) 
Hyperthyroidism 663 (2.6) 433 (2.5) 13 (1.5) 326 (2.4) 920 (2.3) 106 (1.9) 3 (0.7) 91 (2.4) 59 (3.0) 
Hypothyroidism 632 (2.4) 459 (2.6) 6 (0.7) 322 (2.4) 987 (2.5) 126 (2.2) 10 (2.3) 100 (2.6) 59 (3.0) 
COPD 1800 (6.9) 1182 (6.8) 50 (5.8) 926 (6.8) 2408 (6.1) 331 (5.8) 24 (5.5) 220 (5.7) 107 (5.4) 
Liver disease 6207 (24.0) 3668 (21.2) 161 (18.8) 2777 (20.5) 7646 (19.2) 1029 (18.0) 84 (19.1) 742 (19.2) 384 (19.2) 
Hypertrophic cardiomyopathy 51 (0.2) 40 (0.2)  0 (0.0) 18 (0.1) 61 (0.2) 14 (0.2)  0 (0.0) 2 (0.1) 1 (0.1) 
Osteoporosis 7279 (28.1) 5090 (29.4) 251 (29.3) 3758 (27.7) 12018 (30.2) 1749 (30.6) 117 (26.6) 1169 (30.2) 666 (33.4) 
Venous thromboembolism 189 (0.7) 124 (0.7) 5 (0.6) 89 (0.7) 221 (0.6) 30 (0.5) 3 (0.7) 19 (0.5) 6 (0.3) 
Coagulation or platelet defect 227 (0.9) 148 (0.9) 9 (1.1) 105 (0.8) 330 (0.8) 63 (1.1) 4 (0.9) 36 (0.9) 14 (0.7) 
Abbreviations: COPD, chronic obstructive pulmonary disease, SD, standard deviation. 
Low stands for low cardiovascular health, mod for moderate cardiovascular health, high for high cardiovascular health. 
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Table S10. Change in cardiovascular health status, and association with subsequent incident cardiovascular disease and all-cause mortality after 
weighting to account for attrition. 
Change in CVH Status 




Rate per 1000 
Person-Years 
(95% CI) 









Rate per 1000 
Person-Years 
(95% CI) 






Elderly (60~74 years) 5942/91634    6020/91634    
Consistently low 1937/22470  
18.0 
(17.2-18.8) 
Ref 1 (Ref) 1619/22470 
14.5 
(13.8-15.2) 
Ref 1 (Ref) 











(-1.1 to 1.2) 
1.00 
(0.92-1.08) 











(-6.8 to 1.6) 
0.84 
(0.61-1.15) 











(-1.5 to 0.9) 
0.95 
(0.87-1.03) 











(-2.3 to -0.5) 
0.91 
(0.85-0.97) † 











(-4.2 to -0.7) 
0.88 
(0.77-1.00) 











(-11.3 to 0.3) 
0.57 
(0.35-0.94) 











(-4.4 to -0.2) 
0.87 
(0.75-1.01) 











(-9.8 to -4.0) 
0.58 
(0.44-0.77) † 
Very-elderly ( 75 years) 1846/17695    2953/17695    
Consistently low 493/3898  
30.0 
(27.4-32.8) 
Ref 1 (Ref) 679/3898  
39.4 
(36.5-42.5) 
Ref 1 (Ref) 











(-4.7 to 4.6) 
0.96 
(0.85-1.09) 











(-13.6 to 19.6) 
1.03 
(0.69-1.54) 











(-4.2 to 5.9) 
0.95 
(0.83-1.08) 
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(-12.9 to 0.8) 
0.81 
(0.67-0.99) 











(-23.3 to 18.6) 
0.78 
(0.45-1.32) 











(-13.3 to 4.1) 
0.81 
(0.63-1.03) 











(-26.6 to 0.7) 
0.60 
(0.39-0.91) 
Abbreviations: ARD, absolute rate difference; CI, confidence interval, CVH, cardiovascular health; HR, hazard ratio; sHR, subhazard ratio. 
a. sHRs were adjusted for sex, age, economic status, Hospital Frailty Score, living in metropolitan cities, and competing risk of death. 
b. HRs were adjusted for sex, age, economic status, Hospital Frailty Score, and living in metropolitan cities.  
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Table S11. Number of participants according to change in the level of individual cardiovascular health metrics between first and second 
examinations. 
Pattern of change Low-Low Low-Mod Low-High Mod-Low Mod-Mod Mod-High High-Low High-Mod High-High 
Elderly (60~74 years)          
Smoking 10085 (10.9%) 1664 (1.8%) 3943 (4.3%) 940 (1%) 2722 (2.9%) 3082 (3.3%) 3182 (3.4%) 3926 (4.2%) 62926 (68.1%) 
Body mass index 3662 (4%) 879 (1%) 1117 (1.2%) 828 (0.9%) 23167 (25.1%) 5855 (6.3%) 1319 (1.4%) 5336 (5.8%) 50307 (54.4%) 
Physical activity 24819 (26.8%) 12130 (13.1%) 10247 (11.1%) 5349 (5.8%) 9910 (10.7%) 8642 (9.3%) 2945 (3.2%) 5528 (6%) 12900 (14%) 
Blood pressure                        30285 (32.8%) 15663 (16.9%) 4766 (5.2%) 14215 (15.4%) 11410 (12.3%) 2933 (3.2%) 4612 (5%) 3062 (3.3%) 5524 (6%) 
Total cholesterol 4978 (5.4%) 5764 (6.2%) 1991 (2.2%) 5471 (5.9%) 22392 (24.2%) 10301 (11.1%) 1281 (1.4%) 9513 (10.3%) 30779 (33.3%) 
Fasting glucose 4495 (4.9%) 3703 (4%) 1083 (1.2%) 3878 (4.2%) 14801 (16%) 10990 (11.9%) 1117 (1.2%) 12597 (13.6%) 39806 (43%) 
Very-elderly ( 75 years)          
Smoking 1340 (7.9%) 259 (1.5%) 735 (4.3%) 127 (0.7%) 424 (2.5%) 643 (3.8%) 511 (3%) 788 (4.6%) 12134 (71.5%) 
Body mass index 1009 (5.9%) 140 (0.8%) 481 (2.8%) 123 (0.7%) 2863 (16.9%) 1029 (6.1%) 619 (3.6%) 852 (5%) 9845 (58%) 
Physical activity 4820 (28.4%) 2664 (15.7%) 2074 (12.2%) 734 (4.3%) 1652 (9.7%) 1414 (8.3%) 478 (2.8%) 1092 (6.4%) 2033 (12%) 
Blood pressure                        6055 (35.7%) 2996 (17.7%) 768 (4.5%) 2752 (16.2%) 2023 (11.9%) 445 (2.6%) 743 (4.4%) 447 (2.6%) 732 (4.3%) 
Total cholesterol 877 (5.2%) 973 (5.7%) 383 (2.3%) 975 (5.7%) 3861 (22.8%) 1827 (10.8%) 218 (1.3%) 1681 (9.9%) 6166 (36.4%) 
Fasting glucose 746 (4.4%) 722 (4.3%) 320 (1.9%) 705 (4.2%) 2776 (16.4%) 2136 (12.6%) 296 (1.7%) 2430 (14.3%) 6830 (40.3%) 
Low stands for low cardiovascular health, mod for moderate cardiovascular health, high for high cardiovascular health. 
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Table S12. Incidence rates for cardiovascular disease and all-cause mortality according to change in the individual cardiovascular health metrics 
between first and second examinations. 
 Incidence Rate per 1000 Person-Years (95% confidence intervals) 
Pattern of change Low-Low Low-Mod Low-High Mod-Low Mod-Mod Mod-High High-Low High-Mod High-High 
Incident cardiovascular disease 
Elderly (60~74 years) 
Smoking 20.5 (19.2-21.9) 17.3 (14.2-20.7) 16.7 (15.0-18.7) 18.2 (14.5-22.6) 15.8 (13.4-18.6) 16.0 (14.0-18.2) 16.4 (14.5-18.5) 16.1 (14.2-18.1) 12.0 (11.6-12.4) 
Body mass index 15.4 (12.9-18.2) 13.0 (9.8-16.8) 29.4 (11.8-60.6) 13.3 (10.1-17.3) 14.0 (13.3-14.7) 14.2 (12.8-15.6) 30.3 (14.5-55.7) 13.2 (11.9-14.7) 13.6 (13.2-14.1) 
Physical activity 15.6 (14.5-16.3) 13.6 (12.7-14.5) 13.7 (12.7-14.8) 14.3 (13.0-15.7) 10.7 (9.8-11.7) 12.4 (11.2-13.6) 13.9 (12.2-15.8) 13.2 (11.7-14.9) 12.0 (10.913.1) 
Blood pressure 17.4 (16.5-18.4) 15.4 (14.5-16.3) 12.3 (10.1-14.9) 15.1 (14.1-16.1) 13.4 (12.8-14.0) 9.4 (8.3-10.6) 14.0 (11.4-17.0) 9.8 (8.7-11.0) 7.2 (6.2-8.4) 
Total cholesterol 18.9 (17.2-20.8) 14.1 (12.8-15.6) 16.5 (14.0-19.3) 13.6 (12.2-15.1) 13.4 (12.7-14.1) 13.7 (12.7-14.8) 18.0 (14.8-21.7) 14.2 (13.1-15.3) 12.7 (12.2-13.3) 
Fasting glucose 23.6 (21.5-25.9) 20.2 (18.1-22.5) 15.2 (12.1-18.9) 20.1 (18.1-22.3) 15.5 (14.6-16.5) 12.3 (11.3-13.3) 18.5 (15.1-22.5) 12.6 (11.8-13.6) 11.6 (11.1-12.1) 
Very-elderly ( 75 years) 
Smoking 38.5 (33.1-44.6) 36.8 (25.4-51.7) 30.7 (24.9-37.6) 26.5 (14.5-44.4) 25.3 (17.5-35.3) 30.8 (24.2-38.6) 25.7 (19.5-33.1) 26.4 (20.8-33.0) 23.6 (22.3-24.9) 
Body mass index 29.2 (19.7-41.6) 23.3 (12.8-39.1) 42.0 (8.7-122.6) 32.4 (18.9-51.9) 21.0 (18.6-23.7) 29.2 (24.5-34.5) 37.8 (10.3-9.7) 28.1 (23.0-33.9) 26.1 (24.7-27.7) 
Physical activity 29.0 (27.0-31.2) 25.6 (22.8-28.7) 22.5 (19.4-25.9) 25.0 (20.3-30.5) 22.6 (18.6-27.1) 20.7 (16.6-25.6) 32.1 (25.4-40.1) 22.2 (17.2-28.2) 20.7 (17.1-24.8) 
Blood pressure 29.3 (26.4-32.5) 28.6 (25.8-31.6) 20.6 (13.8-29.6) 28.1 (25.1-31.4) 23.5 (21.5-25.6) 20.5 (15.8-26.1) 28.0 (19.5-38.9) 17.9 (13.5-23.3) 15.4 (10.9-21.0) 
Total cholesterol 26.9 (21.9-32.6) 27.4 (22.5-33.0) 27.1 (19.6-26.6) 27.7 (22.8-33.3) 24.9 (22.5-27.5) 23.3 (20.0-27.0) 29.1 (18.8-42.9) 26.9 (23.2-31.0) 25.3 (23.3-27.3) 
Fasting glucose 39.0 (32.1-46.9) 30.7 (24.9-37.5) 34.2 (25.2-45.5) 33.7 (27.4-41.1) 26.5 (23.6-29.7) 23.1 (20.1-26.6) 28.0 (19.4-39.1) 24.4 (21.5-27.7) 23.0 (21.3-24.9) 
All-cause mortality 
Elderly (60~74 years) 
Smoking 25.7 (24.3-27.3) 21.9 (18.5-25.7) 21.3 (19.4-23.5) 19.2 (15.4-23.5) 15.0 (12.7-17.7) 16.2 (14.2-18.4) 19.4 (17.4-21.6) 16.0 (14.2-18.0) 10.5 (10.1-10.9) 
Body mass index 10.7 (8.7-13.0) 10.4 (7.6-13.8) 16.2 (4.4-41.4) 13.0 (9.8-16.9) 10.3 (9.7-10.9) 14.2 (12.8-15.6) 8.3 (1.8-24.3) 11.8 (10.5-13.1) 15.5 (15.0-16.0) 
Physical activity 15.8 (15.2-16.5) 14.0 (13.1-15.0) 13.3 (12.3-14.4) 13.9 (12.6-15.3) 10.6 (9.7-11.6) 11.3 (10.2-12.5) 13.9 (12.2-15.8) 12.2 (10.7-13.7) 11.5 (10.5-12.6) 
Blood pressure 14.8 (13.9-15.7) 14.5 (13.6-15.3) 14.7 (12.3-17.5) 14.0 (13.1-15.0) 13.3 (12.7-13.9) 12.3 (11.0-13.7) 14.2 (11.7-17.2) 11.9 (10.7-13.3) 12.1 (10.8-13.6) 
Total cholesterol 12.2 (10.8-13.6) 11.4 (10.2-12.8) 13.6 (11.4-16.2) 11.6 (10.3-12.9) 10.7 (10.1-11.3) 14.0 (13.0-15.1) 18.2 (15.1-21.8) 13.1 (12.1-14.2) 16.7 (16.0-17.3) 
Fasting glucose 21.5 (19.5-23.6) 18.9 (16.9-21.1) 19.8 (16.3-23.9) 17.5 (15.7-19.5) 14.7 (13.8-15.7) 13.2 (12.3-14.2) 19.7 (16.2-23.7) 12.6 (11.7-13.5) 11.7 (11.2-12.2) 
Very-elderly ( 75 years) 
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Body mass index 19.4 (12.0-29.6) 24.1 (13.5-39.8) 54.4 (14.8-13.9) 32.4 (19.2-51.2) 25.9 (23.3-28.8) 44.4 (38.7-50.7) 53.8 (19.7-11.7) 39.0 (33.2-45.6) 43.5 (41.7-45.5) 
Physical activity 47.1 (44.5-49.8) 38.7 (35.2-42.4) 32.8 (29.1-36.8) 39.9 (34.0-46.6) 35.5 (30.6-41.0) 29.9 (25.0-35.6) 45.8 (37.9-54.9) 32.2 (26.2-39.1) 27.6 (23.5-32.2) 
Blood pressure 39.0 (35.7-42.6) 42.1 (38.8-45.7) 48.1 (37.5-60.8) 40.2 (36.7-44.1) 37.0 (34.5-39.6) 39.5 (33.0-46.9) 41.5 (31.2-54.2) 39.1 (32.5-46.6) 38.2 (31.0-46.5) 
Total cholesterol 34.7 (29.1-41.0) 32.8 (27.6-38.8) 42.0 (32.7-53.1) 34.7 (29.3-40.7) 29.7 (27.1-32.5) 38.2 (34.0-42.7) 53.4 (39.4-70.8) 40.2 (35.7-45.1) 47.8 (45.2-50.6) 
Fasting glucose 57.5 (49.3-66.7) 45.5 (38.5-53.4) 41.4 (31.6-53.3) 53.9 (46.0-62.8) 39.6 (36.1-43.4) 37.3 (33.4-41.5) 52.4 (40.5-66.7) 37.1 (33.5-41.0) 36.0 (33.8-38.3) 
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Table S13. Associations between 4 groups of change in cardiovascular health as defined in the Framingham study and incident cardiovascular 
disease and all-cause mortality. 
Change in CVH status a Elderly (60~74 years) Very-elderly ( 75 years) 
Incident cardiovascular disease No./Total No. Adjusted sHR (95% CI) b No./Total No. Adjusted sHR (95% CI) b 
Low-low 1764/39326 1.97 (1.84-2.10) 569/7091 1.69 (1.50-1.90) 
Low-high 524/7344 1.42 (1.33-1.51) 176/1546 1.12 (0.99-1.27) 
High-low 1803/25893 1.55 (1.40-1.71) 464/4519 1.36 (1.15-1.61) 
High-high 1889/19907 1 [Reference] 556/3805 1 [Reference] 
All-cause mortality No./Total No. Adjusted HR (95% CI) c No./Total No. Adjusted HR (95% CI) c 
Low-low 1997/39326 1.62 (1.52-1.73) 975/7091 1.46 (1.33-1.60) 
Low-high 563/7344 1.11 (1.04-1.19) 320/1546 0.99 (0.90-1.09) 
High-low 1658/25893 1.39 (1.27-1.53) 702/4519 1.39 (1.22-1.57) 
High-high 1881/19907 1 [Reference] 834/3805 1 [Reference] 
Abbreviations: CI, confidence interval; CVH, cardiovascular health; HR, hazard ratio; sHR, subhazard ratio. 
a. The 4 groups of change in CVH were defined as high‐high (those with CVH score ≥8 at baseline and last score of ≥8, reference category), high‐low (≥8 
baseline and ≤7 last), low‐high (≤7 baseline and ≥8 last) and low‐low (≤7 baseline and ≤7 last) as used in the Framingham Offspring Study. 
b. sHRs were adjusted for sex, age, economic status, Hospital Frailty Score, living in metropolitan cities, and competing risk of death. 
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Figure S1. Summary of the statistical analysis design. Gray lines represent the enrollment of patients in this study cohort. Red line represent analysis 
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Figure S2. Distribution of the change in cardiovascular health between 1st and 2nd examination in the total study population (n=109,769) (A), in 
individuals aged <75 (n=92,490) and ≥70 years (n=16,961) (B), in women (n=60,135) and men (n=49,296) (C), and in high (n=50,330) and non-high 
(n=59,101) economic status (D). CVH, cardiovascular health. 
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Figure S3. Kaplan–Meier curves of incident cardiovascular disease and all-cause mortality according 
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